2024
Interleukin-16 is increased in dialysis patients but is not a cardiovascular risk factor
Brösecke F, Pfau A, Ermer T, Dein Terra Mota Ribeiro A, Rubenbauer L, Rao V, Burlein S, Genser B, Reichel M, Aronson P, Coca S, Knauf F. Interleukin-16 is increased in dialysis patients but is not a cardiovascular risk factor. Scientific Reports 2024, 14: 11323. PMID: 38760468, PMCID: PMC11101424, DOI: 10.1038/s41598-024-61808-7.Peer-Reviewed Original ResearchConceptsIL-16 levelsIL-16Dialysis patientsCardiovascular eventsConcentrations of IL-16Kidney failureUremic toxinsCardiovascular diseaseCompared to healthy individualsPlasma oxalate concentrationActivated immune cellsAssociated with cardiovascular diseaseIL-16 concentrationCytokine IL-16Cardiovascular risk factorsNo significant associationPlasma oxalateInflammatory markersImmune cellsCytokine concentrationsInterleukin-16US patientsCohort 1Cardiovascular outcomesHealthy individuals
2022
Oxalate homeostasis
Ermer T, Nazzal L, Tio M, Waikar S, Aronson P, Knauf F. Oxalate homeostasis. Nature Reviews Nephrology 2022, 19: 123-138. PMID: 36329260, PMCID: PMC10278040, DOI: 10.1038/s41581-022-00643-3.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsHomeostasisHumansHyperoxaluriaKidneyOxalatesRenal DialysisRenal InsufficiencyRenal Insufficiency, ChronicConceptsKidney diseaseOxalate homeostasisAnti-inflammatory medicationsChronic kidney diseaseKidney replacement therapySudden cardiac deathProgressive kidney diseaseOutlook of patientsOxalate nephropathyCardiovascular complicationsSystemic inflammationCardiac deathReplacement therapySecondary hyperoxaluriaKidney failureElevated plasmaConsequent impairmentNovel therapeuticsPatientsDiseaseEffective elimination strategiesEndogenous sourcesHomeostasisElimination strategyExcretionAuthors’ Reply: Calcium-Based Phosphate Binders and Plasma Oxalate Concentration in Dialysis Patients
Pfau A, Knauf F. Authors’ Reply: Calcium-Based Phosphate Binders and Plasma Oxalate Concentration in Dialysis Patients. Journal Of The American Society Of Nephrology 2022, 33: 1428-1428. PMID: 35500939, PMCID: PMC9257799, DOI: 10.1681/asn.2022030359.Peer-Reviewed Original ResearchHemodialysis and biotransformation of erythrocyte epoxy fatty acids in peripheral tissue
Liu T, Dogan I, Rothe M, Kunz J, Knauf F, Gollasch M, Luft F, Gollasch B. Hemodialysis and biotransformation of erythrocyte epoxy fatty acids in peripheral tissue. Prostaglandins Leukotrienes And Essential Fatty Acids 2022, 181: 102453. PMID: 35633593, DOI: 10.1016/j.plefa.2022.102453.Peer-Reviewed Original ResearchConceptsRed blood cellsHD treatmentHemodialysis treatmentEnd-stage renal disease patientsHydroxyeicosatetraenoic acidHydroxyeicosapentaenoic acidSingle hemodialysis treatmentChronic kidney diseaseRenal disease patientsRenal replacement therapyFatty acid statusVenous blood samplesHydroxydocosahexaenoic acidEpoxy fatty acidsCause of mortalityLOX pathwayRenal failureFatty acidsKidney diseaseDisease patientsVenous bloodCardiovascular functionAcid statusArteriovenous differenceCardiovascular disease